Anti-CD74 IGA antibodies, genetic polymorphisms and inflammatory activity in ankylosing spondylitis

Anti-CD74 IGA antibodies, genetic polymorphisms and inflammatory activity in ankylosing spondylitis

IgA anti-CD74 can be a promising marker for diagnosis, assessment of activity and prognosis for ankylosing spondylitis.The aim of the study was to determine the level of IgA anti-CD74 in patients with ankylosing spondylitis and to evaluate its relationships with ankylosing spondylitis activity and c...

Full description

Saved in:

Bibliographic Details
Main Authors:	V. I. Mazurov, I. Z. Gaydukova, E. A. Vasilenko, S. V. Lapin, I. V. Kholopova, M. A. Korolev
Format:	Article
Language:	Russian
Published:	IMA PRESS LLC 2021-01-01
Series:	Научно-практическая ревматология
Subjects:	axial spondyloarthritis ankylosing spondylitis anti-cd74 il-17
Online Access:	https://rsp.mediar-press.net/rsp/article/view/2963
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Long-term efficacy and safety of netakimab in the treatment of ankylosing spondylitis: results of Phase III international, multicenter, randomized double-blind clinical trial BCD-085-5/ASTERA
by: V. I. Mazurov, et al.
Published: (2020-11-01)

CLINICAL EXPERIENCE WITH ETANERCEPT IN THE TREATMENT OF PATIENTS WITH ANKYLOSING SPONDYLITIS
by: O. A. Rumyantseva, et al.
Published: (2018-05-01)

Specific features of axial spondyloarthritis, including ankylosing spondylitis and psoriatic arthritis, in persons of different genders
by: A. P. Rebrov, et al.
Published: (2015-03-01)

Remission in ankylosing spondylitis and axial spondyloarthritides: A modern understanding of the problem
by: I. Z. Gaydukova, et al.
Published: (2016-03-01)

Efficacy and safety of a new original interleukin 17A inhibitor in the treatment of patients with active ankylosing spondylitis: results of a basic (BCD-085-3/AILAS) and extended (BCD-085-3ext/AILAS-II) phase II clinical trial
by: Sh. Erdes, et al.
Published: (2019-12-01)

Ankylosing Spondylitis
by: Nazanin Ebrahimiadib, et al.
Published: (2021-07-01)

Efficacy and safety of netakimab, anti-IL-17A monoclonal antibody, in patients with ankylosing spondylitis. Results of phase III international, multicenter, randomized double-blind clinical trial BCD-085-5/ASTERA
by: V. I. Mazurov, et al.
Published: (2020-09-01)

COMPARATIVE EVALUATION OF PATIENTS WITH ANKYLOSING SPONDYLITIS AND NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS
by: I. А. Cherentsova, et al.
Published: (2016-09-01)

Pharmacoeconomic analysis of netakimab in the treatment of ankylosing spondylitis: perspective of Russian healthcare system
by: A. V. Rudakova, et al.
Published: (2025-02-01)

Features of ankylosing spondylitis at different stages in men and women
by: I. A. Cherentsova, et al.
Published: (2019-05-01)

Real-world retention rate, effectiveness, and safety of netakimab in the treatment of patients with ankylosing spondylitis: Two-year results of the real word evidence LIBRA study
by: Sh. F. Erdes, et al.
Published: (2025-07-01)

TUMOR NECROSIS FACTOR-α INHIBITORS IN THE TREATMENT OF AXIAL SPONDYLOARTHRITIS, INCLUDING ANKYLOSING SPONDYLITIS
by: S. A. Lapshina, et al.
Published: (2016-09-01)

USE OF NONSTEROIDAL ANTI-INFLAMMATORY DRUGS FOR THE TREATMENT OF AXIAL SPONDYLOARTHRITIS, INCLUDING ANKYLOSING SPONDYLITIS, MONITORING THEIR EFFICACY AND SAFETY (DRAFT GUIDELINES OF THE EXPERT SPONDYLOARTHRITIS DIAGNOSIS AND TREATMENT GROUP)
by: I. Z. Gaidukova, et al.
Published: (2016-09-01)

THE NEED AND POSSIBILITIES OF EARLY DIAGNOSIS OF ANKYLOSING SPONDYLITIS: COMMENTARIES ON THE PAPER «EARLY DIAGNOSIS OF ANKYLOSING SPONDYLITIS» (No. 4, 2013) AND DISCUSSION IN THE JOURNAL (No. 2, 2014)
by: Sh. F. Erdes
Published: (2014-09-01)

The Level of IgA Antibodies to CD74 in Patients with Spondyloarthritis and Degenerative-Dystrophic Diseases of the Spine
by: A. P. Rebrov, et al.
Published: (2022-08-01)

LABORATORY BIOMARKERS FOR ANKYLOSING SPONDYLITIS
by: E. N. Aleksandrova, et al.
Published: (2017-03-01)

Evaluation of the possibility of axial psoriatic arthritis patients meet classification criteria for axial spondyloarthritis and ankylosing spondylitis
by: E. E. Gubar, et al.
Published: (2023-08-01)

Disease activity and two-year sacroiliac joint changes according to instrumental study findings in a CoRSAr cohort of patients with early axial spondyloarthritis
by: Sh. Erdes, et al.
Published: (2019-05-01)

Ankylosing spondylitis morbidity trends in Russia and Saturday spondyloarthritis schools
by: Shandor Fedorovich Erdes, et al.
Published: (2013-04-01)

Course of uveitis in patients with ankylosing spondylitis during the interleukin 17 inhibitors therapy
by: A. A. Godzenko, et al.
Published: (2023-10-01)

Factors of coxitis progression in patients with axial spondyloarthritis. Results of a two-year dynamic observation
by: E. M. Agafonova, et al.
Published: (2024-12-01)

ASSESSMENT OF COXITIS PROGRESSION IN EARLY AXIAL SPONDYLOARTHRITIS
by: E. M. Agafonova, et al.
Published: (2020-04-01)

THE EVOLUTION OF AXIAL SPONDYLOARTHRITIS DURING 12-MONTH FOLLOW-UP STUDY OF A CORSAR COHORT
by: Sh. F. Erdes, et al.
Published: (2016-09-01)

Time course of radiographic hip joint changes in patients with early axial spondyloarthritis
by: E. M. Agafonova, et al.
Published: (2021-02-01)

Efficacy of golimumab in treating uveitis in patients with ankylosing spondylitis
by: T. V. Dubinina, et al.
Published: (2016-09-01)

REMISSION IN AXIAL SPONDYLOARTHRITIS: DEFINITION AND EVALUATION TOOLS (RECOMMENDATIONS OF THE SPONDYLOARTHRITIS STUDY GROUP OF EXPERTS, ALL-RUSSIAN PUBLIC ORGANIZATION «THE ASSOCIATION OF RHEUMATOLOGY OF RUSSIA»)
by: I. Z. Gaidukova, et al.
Published: (2018-03-01)

INTERLEUKIN-17A IS A NEW TARGET OF ANTICYTOKINE THERAPY FOR ANKYLOSING SPONDYLITIS
by: Sh. F. Erdes
Published: (2016-09-01)

Spondyloarthritis in India
by: Anand N Malaviya
Published: (2020-01-01)

Progression of sacroiliitis in men and women according to the cohort of early axial spondyloarthritis (CORSAR) over 3 years of follow-up
by: D. G. Timokhina, et al.
Published: (2021-12-01)

Recent advances and prospects of axial spondyloarthritis / ankylosing spondylitis treatment
by: Sh. F. Erdes
Published: (2021-04-01)

STEM CELL TRANSPLANTATION AS A POSSIBLE STRATEGY FOR TREATING STANDARD THERAPY-RESISTANT ANKYLOSING SPONDYLITIS
by: I. Z. Gaidukova, et al.
Published: (2016-12-01)

COMPARATIVE ANALYSIS OF MAIN CLINICAL MANIFESTATIONS IN MALES AND FEMALES WITH EARLY AXIAL SPONDYLOARTHRITIS
by: D. G. Rumyantseva, et al.
Published: (2019-09-01)

DRAFT «ASPINE» MOBILE APPLICATION FOR PATIENTS WITH EARLY AXIAL SPONDYLOARTHRITIS
by: D. G. Rumiantceva, et al.
Published: (2018-01-01)

Clinical picture of ankylosing spondylitis in HLA-B27 positive and negative patients
by: Sh. F. Erdes, et al.
Published: (2023-10-01)

COURSE OF UVEITIS IN PATIENTS WITH ANKYLOSING SPONDYLITIS
by: A. A. Godzenko, et al.
Published: (2016-09-01)

EXPERIENCE WITH RITUXIMAB IN PATIENTS WITH ANKYLOSING SPONDYLITIS
by: Mikhail Sergeyevich Protopopov, et al.
Published: (2013-02-01)

Long-term efficacy and safety of netakimab in patients with active ankylosing spondylitis: results of three years of use in the international multicentre, randomized, double-blind, phase III clinical trial BCD-085-5/ASTERA
by: V. I. Mazurov, et al.
Published: (2024-02-01)

Radiologic methods as a tool for monitoring axial spondyloarthritis in real clinical practice
by: T. V. Dubinina, et al.
Published: (2022-02-01)

Musculoskeletal losses in patients with ankylosing spondylitis
by: T. A. Raskina, et al.
Published: (2019-10-01)

Coxitis in patients with ankylosing spondylitis: clinicoradio logic comparisons
by: A. G. Bochkova, et al.
Published: (2005-08-01)